drugset

drugset / Trial / NCT00046800

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

NCT00046800 ↗

Phase 2 Completed 80 enrolled Astellas Pharma Inc OSI Pharmaceuticals · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.

Timeline

Start: 2002-09
Primary completion: —
Completion: 2003-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OSI-211	Unknown	—	—

Indications